Cargando…

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)

Felcisetrag (formerly known as TAK‐954) is a selective serotonin receptor agonist under investigation for use in patients with postoperative gastrointestinal dysfunction. The safety, tolerability, and pharmacokinetics (PK) of intravenous (i.v.) felcisetrag have been studied, but little is known abou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czerniak, Richard, Cieslarová, Blanka, Kupčová, Viera, Rosario, Maria, Lock, Ruth, Dong, Cheng, Dukes, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Special Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542772/ https://www.ncbi.nlm.nih.gov/pubmed/35253917 http://dx.doi.org/10.1002/jcph.2044

Ejemplares similares

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2022)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment
por: Torres, Rosarelis, et al.
Publicado: (2015)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
por: Hoover, Randall K., et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2021)

Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis
por: Wei, Jia-Fu, et al.
Publicado: (2020)

Sympathetic autonomic dysfunction and impaired cardiovascular performance in higher risk surgical patients: implications for perioperative sympatholysis
por: Whittle, John, et al.
Publicado: (2015)

Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX‐02 in Patients With Nephropathic Cystinosis
por: Haverty, Thomas, et al.
Publicado: (2021)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT(4) Receptor Agonist
por: Pusalkar, Sandeepraj, et al.
Publicado: (2022)

Randomised study: effects of the 5‐HT(4) receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis
por: Chedid, Victor, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
por: Taylor, Lesley, et al.
Publicado: (2019)

Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction
por: Andell, Pontus, et al.
Publicado: (2014)

Access to Medicaid and Medicare by the low-income disabled
por: Ellwood, Marilyn Rymer, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_3jortbh2a7igoaca372qvcai6o